Evidence map›Paper›PMID 31312203›Full record

ArticleFrontiers in immunology2019

Immunoglobulin Therapy in a Patient With Severe Chikungunya Fever and Vesiculobullous Lesions.

Ana Isabel V Fernandes, Joelma R Souza, Adriano R Silva, Sara B S C Cruz, Lúcio R C Castellano

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Chikungunya fever.Nature reviews. Disease primers · 2023
    Review
  3. Review
  4. Article
  5. Development and Application of Treatment for Chikungunya Fever.Research and reports in tropical medicine · 2022
    Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ana Isabel V FernandesHuman Immunology Research and Education Group-GEPIH, Escola Técnica de Saúde da UFPB, Universidade Federal da Paraíba, João Pessoa, Brazil.
Joelma R SouzaHuman Immunology Research and Education Group-GEPIH, Escola Técnica de Saúde da UFPB, Universidade Federal da Paraíba, João Pessoa, Brazil.
Adriano R SilvaDivision for Infectious and Parasitic Diseases, Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba, João Pessoa, Brazil.
Sara B S C CruzHuman Immunology Research and Education Group-GEPIH, Escola Técnica de Saúde da UFPB, Universidade Federal da Paraíba, João Pessoa, Brazil.
Lúcio R C CastellanoHuman Immunology Research and Education Group-GEPIH, Escola Técnica de Saúde da UFPB, Universidade Federal da Paraíba, João Pessoa, Brazil.
Universidade Federal da Paraíba · BRHospital Universitário Lauro Wanderley · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chikungunya virus (CHIKV) is an emerging arbovirus whose transmission has already been reported in several countries. Although the majority of individuals acutely infected with CHIKV appear to become asymptomatic, reports showing the occurrence of atypical and severe forms of the disease are increasing. Among them, the neurological and skin manifestations require medical attention. Treatment of CHIKV infection is almost symptomatic. In this sense, we report the case of a 56-years-old man who presented fever, headaches, paresthesia and pain in the right arm with visible red spots on the skin starting 30 days before Hospital admission. Tests determined Chikungunya infection and excluded other co-morbidities. Disease evolved with edema in hands and feet and extensive hemorrhagic bullous lesions on the skin of upper and lower limbs. Variations in hematological counts associated with liver dysfunction determined this patient's admission to the Intensive Care Unit. Then, he received intravenous antibiotic and immunoglobulin therapy (400 mg/Kg/day for the period of 5 days) with total recovery from the lesions after 10 days of follow-up. A general improvement in blood cell count and successful wound healing was observed. After discharge, no other clinical sign of the disease was reported until nowadays. This case reports for the first time the successful administration of intravenous immunoglobulin therapy to a patient with severe atypical dermatological form of Chikungunya Fever without any associated comorbidity.

Indexed as

Anti-Bacterial AgentsAntibodies, ViralChikungunya FeverChikungunya virusFollow-Up StudiesHumansImmunization, PassiveImmunoglobulins, IntravenousIntensive Care UnitsMaleMiddle AgedSkin Diseases, VesiculobullousTreatment OutcomeAnti-Bacterial AgentsAntibodies, ViralImmunoglobulins, IntravenousChikungunya feverflebogamma DIFintensive careintravenous antibodiestherapeutics

Identifiers

PMID31312203
PMCPMC6614379
OpenAlexW2951812365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.